Featured Research

from universities, journals, and other organizations

Setting the stage for a new paradigm in treatment of heart failure

Date:
January 30, 2013
Source:
University of North Carolina School of Medicine
Summary:
New evidence shows the root of heart failure lies in misfolded proteins in the heart’s cells. The finding may pave the way for dramatically new treatment approaches.

Despite a substantial increase in the number of people suffering the debilitating and often deadly effects of heart failure, treatments for the condition have not advanced significantly for at least 10 years. An analysis by researchers at the University of North Carolina School of Medicine shows new breakthroughs could be closer than we thought.

The analysis points to striking similarities between heart cells in patients with heart failure and brain cells in patients with Alzheimer's disease, raising the possibility that some treatment approaches being developed for Alzheimer's may also help reverse the damage from heart failure.

"We know that Alzheimer's is a process of wear and tear on the brain, and the same sort of wear and tear affects the heart," said Cam Patterson, MD, MBA, UNC's chief of cardiology. "The good news is now that we recognize that -- and can understand how the wear and tear actually affects proteins in the heart -- it offers us a new chance to identify strategies to reverse that wear and tear. It's like providing a key to preventing aging of the heart."

The analysis, co-authored by Patterson and Monte Willis, MD, PhD, associate professor of pathology and laboratory medicine at UNC, appears in the Jan. 31, 2013 issue of the New England Journal of Medicine.

The researchers say a variety of recent studies point to one conclusion: misfolded proteins in heart cells are a key factor in the process of heart failure. "There's a convergence of data pointing to this being a real problem," said Patterson.

The analysis brings together three main lines of evidence. First, studies of heart tissue from patients with heart failure reveal large accumulations of misfolded proteins within damaged heart cells, similar to the accumulations found in the brain cells of patients with Alzheimer's. Second, recent studies using mice show heart problems can result from defects in the body's quality-control system for monitoring and maintaining proteins. Finally, studies of a rare genetic disorder link severe heart problems to misfolding of two proteins, known as desmin and CryAB.

The new conclusion opens enticing avenues for possible treatments. Scientists studying Alzheimer's and other neurological disorders have long focused on ways to correct or prevent protein misfolding, and have even developed drugs that accomplish this feat. "This raises the possibility that that same type of strategy, and maybe even some of those compounds, will be beneficial in heart failure," said Patterson. "It's an entirely new treatment paradigm."

Heart failure, in which the heart fails to pump as effectively as it should, is a chronic, debilitating and often deadly condition affecting millions of adults in the United States. It can result from heart attacks, coronary heart disease and many other causes. Increases in heart attack survival rates mean more people are living with the debilitating effects of heart failure, including fatigue, shortness of breath and increased mortality.


Story Source:

The above story is based on materials provided by University of North Carolina School of Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Monte S. Willis, Cam Patterson. Proteotoxicity and Cardiac Dysfunction — Alzheimer's Disease of the Heart? New England Journal of Medicine, 2013; 368 (5): 455 DOI: 10.1056/NEJMra1106180

Cite This Page:

University of North Carolina School of Medicine. "Setting the stage for a new paradigm in treatment of heart failure." ScienceDaily. ScienceDaily, 30 January 2013. <www.sciencedaily.com/releases/2013/01/130130183648.htm>.
University of North Carolina School of Medicine. (2013, January 30). Setting the stage for a new paradigm in treatment of heart failure. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/01/130130183648.htm
University of North Carolina School of Medicine. "Setting the stage for a new paradigm in treatment of heart failure." ScienceDaily. www.sciencedaily.com/releases/2013/01/130130183648.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins